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Delivering optimal cancer care to children, adolescents and adults with ASD has recently
become a healthcare priority and represents a major challenge for all providers involved. In
this review, and after consideration of the available evidence, we concisely deliver key
information on this heterogenous group of neurodevelopmental disorders, as well as
recommendations and concrete tools for the enhanced oncological care of this vulnerable
population of patients.
Keywords: outcome disparities, autism (autism spectrum disorders), cancer, neurodevelopmental disorders,
supportive care, oncology (general), medical oncology, pediatric oncologyINTRODUCTION
Providing care to children, adolescents and adults with cancer requires communicating effectively in
an age- and development-specific way. With the increase in the complexity of healthcare systems
and sophistication of available cancer therapies, individuals with neurodevelopmental challenges,
including autism spectrum disorders (ASD), constitute a particularly vulnerable group for
disparities in access and outcomes. Oncology providers need to become progressively more
educated to the challenges posed by caring for the ASD population and have the necessary tools
to implement effective communication and favorable environments for screening, diagnosis and
therapy of cancer in this setting.
Therefore, our multidisciplinary expert panel of oncologists, nurses, neurologists and autism
mental health specialists (cf. Supplementary Material 1) reviewed the available evidence and
provide a) a concise synthesis of the evidence relevant for the optimal oncological care of patients
with ASD and b) a discussion of recommendations and strategies and on how teams can enhanceJanuary 2021 | Volume 10 | Article 5957341
Vuattoux et al. Cancer Care and Autismtheir care and provide support for these patients and their
families/caregivers in their cancer trajectory.DEFINITION, PREVALENCE, AND CAUSES
OF ASD: REQUIRED BASIC KNOWLEDGE
FOR ALL ONCOLOGY TEAMS
ASD is a neurodevelopmental condition characterized by social
communication deficits, restricted, repetitive and stereotypical
patterns of behavior, interests, or activities, and sensory atypicalities
(1). It is associated with various levels of intellectual and motor
functioning and verbal skills, anxiety, and often with symptoms of
other neurodevelopmental disorders, such as Attention Deficit
Hyperactivity Disorder (ADHD) (2, 3). A subgroup of patients
with ASD without intellectual disability (ID) were referred to/
diagnosed as having Asperger’s syndrome prior to the revision
leading to the DSM-5 classification. In this population, where a
diagnosis is often made later in life, autism without ID remains
unrecognized because clinical manifestations can a) overlap with
other comorbidities of ASD or other psychiatric disorders, and b)
patients, in majority females, can display sophisticated autism
compensatory strategies (e.g., social camouflaging) (4, 5).
ASD is a most likely complex polygenic condition, with both
de novo and rare inherited variants acting on a background of
common genetic polymorphisms. Twin and family studies
support the existence of heritable risk factors in ASD (6–8).
Associations have been found in genes involved in early brain
development (incl. synapse formation/stabilization and
neurotransmission), in particular in the gamma-aminobutyric
acid (GABA)-ergic system (9). Numerous pre-/perinatal risk
factors and environmental exposures have also been suggested
(10–13). Two studies also showed an increased prevalence of
cancer among children with ASD, and recent genome/exome-
wide sequencing studies of de novo and recurrent copy number
variations in ASD and cancer have suggested an overlap in genes
conferring risk for autism and cancer (14–16).
On an epidemiological level, prevalence of ASD has been
steadily increasing over the last two decades, and it is now
estimated at 16·8/1,000 (i.e., 1/59) in children of 8 years of age
in the United States, with a shift in gender ratios (M:F) recently
dropping from 8:1 to of 3:1 (17–19). The increase in prevalence
has been attributed, but not exclusively, to a growth in awareness
of the disorder with younger ages at diagnosis (20, 21).
Additionally, a 2013 revision of the diagnostic criteria part of
the “Diagnostic and Statistical Manual of Mental Disorders”
(DSM-5) classification has led to an increase of diagnoses of
individuals with less severe symptoms (1, 22). Thus, in the past
decade, ASD prevalence increased almost 3.5 fold among children
aged 2–17 years, mainly accounted for by an eightfold increase of
ASD without intellectual disability (17). Alternatively, the increase
prevalence has been speculated to be linked to a combination of
genetic and environmental risk factors (23, 24). ASD sex ratio
variations have been associated with the use of more accurate
diagnostic criteria or could be related to sexually dimorphic
neuroimmune system activation and the microbiome (25, 26).Frontiers in Oncology | www.frontiersin.org 2HEALTHCARE AND CANCER CARE
FOR INDIVIDUALS WITH ASD
Within the population of individuals with high mental health
needs, those with ASD represent a heterogeneous and challenging
group in virtually every healthcare area (4, 27). During their
lifetime, 70% of patients with ASD will be diagnosed with a
medical or psychiatric comorbidity, with a negative impact on
educational/employment outcomes (28, 29). In comparison to the
general population, individuals with ASD have higher prevalence
rates for almost all medical and psychiatric conditions, especially
dyslipidemia, obesity, hypertension, gastrointestinal disorders,
autoimmune conditions, asthma, allergies, infections, epilepsy,
sleep disorders, depression, and visual and hearing impairments
(30–35). How these comorbidities influence the risk of developing
cancer, how they impact its early detection and the delivery of
oncological care, remains unknown.
A recent study based on the United States National Survey of
Children’s Health identified an approximately four times higher
odds of unmet health care needs in children with ASD when
compared to children without disabilities, disproportionately to
children with other disabilities (36). Compiling data from
research across the last decade, two recent reviews underline
the limited availability of specific healthcare services for families
with a child with ASD, and the lack of ASD-specific training in
healthcare providers (37, 38).
As a possible consequence of underutilization of healthcare
resources leading to unmet needs, an increased overall mortality
has been observed in the ASD population (39–41). This is
associated with complications related to different comorbidities
including suicide, accidental death resulting from unsafe
behaviors, use of supplemental medications such as atypical
antipsychotics, poor nutrition, and insufficient/inappropriate
use of healthcare resources (42–45). Specifically, the odds ratio
of death from a neoplasm was estimated to be close to double in
individuals with ASD (1.83 in females, 1.79 in males) when
compared than non-ASD controls (41). This latter analysis was a
matched case cohort study linking two nationwide population-
based Swedish registers including 27’122 individuals with ASD
(n=6240 low-functioning, n=20882 high functioning) and almost
3 million controls. Interestingly, individuals with low-functioning
ASD had a higher OR of death from a neoplasm (2.12, 1.25–3.61
95% CI) than their high-functioning counterparts (1.75, 1.39–2.21
95% CI). As the incidence of cancer in ASD has been measured to
be globally equal to that of the general population, differences in
outcomes are most likely attributable to disparities in optimal
cancer care, ranging from limited access to screening, delayed
diagnosis and ineffective therapy.
While an early and correct diagnosis of ASD facilitates the
deployment of adequate conditions for cancer care, this is possibly
not sufficient. Oncology healthcare providers might lack a
sufficient understanding of these neuro-developmental
conditions, and/or be unaccustomed to the challenges caused by
admitting an individual with ASD to their services (i.e., difficulties
with emotional rigidity, inflexibility, misunderstanding/
misinterpreting social situations, among others). Education and
training in communication have been identified as a priority toJanuary 2021 | Volume 10 | Article 595734
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abilities (46). This is particularly relevant for patients with ASD
who generally are heavily dependent on their proxy-network (e.g.,
parents, siblings, family members in extenso, and other support
providers) for their daily activities and health maintenance.
National programs to improve education and communication
skills of providers have been initiated in several countries,
including the United Kingdom’s National Health Service’s
“Right to be heard” campaign (47).DELIVERING CANCER CARE TO
INDIVIDUALS WITH ASD: POTENTIAL
OBSTACLES AND SOLUTIONS
Oncology teams expect concrete strategies to improve their
understanding of the challenges faced by in/out-patients with
ASD, and to identify their individual needs and the necessary
environmental arrangements. Raising awareness and providing
specific education for all members of the interprofessional team is
the required first step. The abovementioned recent United Kingdom
national policy addresses the rationale for a mandatory nation-wide
staff training in identifying and specifically supporting patients with
autism/learning disabilities and their associated conditions (47).
Among the innovative proposals is the concept that, because face-
to-face educational opportunities trump e-learning, individuals with
ASD should contribute to this training, by advocating for the
community’s needs and challenges.
While we await that other implement similarly ambitious
national strategies, it is key for oncologists and their teams to
have access to information on “red flags”. We therefore summarized
the main features hinting to ASD in Table 1, categorizing them by
age group.
Regarding oncology-specific care recommendations, only
very limited high-grade (i.e., prospective trial) evidence is
unfortunately available on specific plans to adopt for the
optimal oncological care of individuals with ASD at this time
(50, 51). Nonetheless, we decided to summarize these expert-
based recommendations in Table 2, as we feel these measures
could improve care before more extensive evidence is at hand.
We will discuss the main recommendations below.
First, oncology teams need to be particularly vigilant to
children, adolescents and adults with ASD, as their unique
physiological and neuro-psychological (i.e., behavioral, cognitive,
and motor) profiles might cause difficulties in their adherence/
compliance with the “standard of care” clinical strategies in place
for other patients. ASD individuals with cancer have to cognitively
and emotionally grasp the stakes of a serious illness, face invasive
investigations and treatments while dealing with the struggles of a
neurodevelopmental disorder (52). Therefore, oncology providers
need to be aware that the behavioral manifestations and the
communication deficits can pose a particularly significant threat
to the provision of optimal care in this very heterogeneous
population (53, 54). For example, cognitive inflexibility is a key
difficulty that may manifest itself in the context of cancer care,Frontiers in Oncology | www.frontiersin.org 3including in individuals with ASD without ID or a more subtle
phenotype. In this setting, oncology teams unaware of the signs of
ASD might stigmatize patients as poorly adherent/compliant or
“difficult”. Overall, if not addressed, the ASD-specific features of
non-standard communication and behavior carry the risk of
deleteriously impacting clinical service operations and lead to
unforeseen morbidity and mortality.
Second, to meet the needs of individuals with ASD and cancer,
clinicians must imperatively and effectively collaborate with
parent/families and other caregivers with the aims to constantly
adapt communication and monitor/manage the clinical
environment. It cannot be stressed enough that working in
partnership with the parents/caregivers is of key importance to
prioritize and coordinate interventions and treatments, and to
provide adequate supportive care to the patient and his/her family
members/care-proxies. This collaboration needs to be re-evaluated
on a regular basis for the effectiveness in assessing patient- and
caregiver-reported symptoms and issues.
Third, regarding communication, as information is being mostly
provided verbally, healthcare professionals must use appropriate
strategies and tools adjusted to the characteristics of the patient to
facilitate transmission and understanding of information.
Regardless of age and cognitive functioning level, individuals with
ASD generally present strengths in the visual processing of
information whereas they are often “drowned” by the flood of
information presented verbally, particularly in contexts perceived as
stressful. Consequently, a coherent and systematic use of visual aids
by the healthcare team (e.g., images, pictures, and graphics), short
visual scenarios illustrating the steps of a treatment to come, a
“thermometer of emotions” to indicate the level of perceived
discomfort or even pre-established diagrams/drawings at the
bedside can be means to reduce anxiety and prevent a potential
crisis. Examples of visual support methods related to care protocols
for children and adults with ASD have been developed (55). The
Autism Speaks website is a very valuable resource and provides
toolkits for communication in many situations (www.autismspeaks.
org/tool-kit). Knowledge on the patient’s preferred communication
system (e.g., use of pictograms, images, or electronic “tablet”
devices) will allow the prompt identification of needs, facilitate
the integration into new or unexpected environments (incl. new
providers), and allow the establishment of routines.
Fourth, establishing an individualized global care plan and
specific protocols prior to the start of any exam, treatment or
procedure can help the healthcare team to anticipate potential
disruptions. The development of these strategies should always
involve the patient, the family and/or primary caregivers and, to the
extent possible, the expertise of autism specialists and individuals
who themselves present ASD (47). Critical information such as
ASD-specific indicators of severity, of intellectual functioning,
the sensory profile, somatic and psychiatric comorbidities and
whether the individual is verbal or not will need to be gathered
and communicated effectively within the entire team. Oncology
providers need to be aware that caregiver reports about behavioral
changes or changes in physiological patterns can inform the clinical
team about potential problems more swiftly than any other means.
Lastly, the comprehensive and personalized care plan should beJanuary 2021 | Volume 10 | Article 595734
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members in charge of the patient, particularly at shift changes or
other sign-off timepoints. Table 2 provides an overview of our
recommendations to plan, anticipate, react and report in case of
behavioral crises in the clinical environment (Goal C-7). It will beFrontiers in Oncology | www.frontiersin.org 4important to always ensure the latter interventions can be activated
swiftly in out- and inpatient settings.
Fifth, clinical environments rarely adapt to an individual
sensory profile, and patients might associate oncology care
with a particularly hostile experience. This is even moreTABLE 1 | Signs and symptoms of ASD at different ages; screening and diagnostic tools (adapted from (48, 49)).
Age
(years)






- Delay/absence in language prerequisites (e.g., social smile, eye contact, response to his/her
name, joint attention, babbling, pointing, social anticipation and social gestures)
- Delay/atypical language development (no words at 16 months, no spontaneous association
of two-words at 24 months)
- Loss/regression of language or social skills
- Lack of pretend or imaginative play
- Stereotypies (e.g., hand
flapping)/body mannerisms
(e.g., toe walking)
- Atypical play (e.g., lining
up or flipping object or toys)
- Frequent atypical behavior
with reactive tantrum after
minimal stimulation/constraint
- Attachment to unusual




objects close to the eyes,
sniffing them, putting them in
the mouth)
- Excessive reactions or
indifference to physical














- Deficit in socio-emotional reciprocity (e.g., lack of theory of mind, reduced sharing of
emotions or affects)
- Difficulties with pragmatic language (e.g., initiate and maintain a normal conversation that is
far removed from one’s interests, limited or, conversely, very elaborate conversation and
vocabulary about one’s interests, failure in back-and-forth conversation, difficulties with
sarcasm and metaphors, stereotyped and repetitive use of language, strange prosody)
- Social difficulties and peculiarities with other children (e.g., difficulty playing with other
children, developing and maintain friendships, adjusting behavior to different social
contexts)
- Difficulties in relationships with adults (e.g., excessive intensity/distance)




- Narrow or circumscribed
interests (e.g., dinosaurs,
numbers)
- Special preference for
atypical interests or activities
(e.g., collecting, calculating,
making lists)
- Atypical sensory reactions
(e.g., inappropriate or
adverse responses to
specific sounds or textures)
- Excessive reactions or
indifference to pain or
temperature










- Social awkwardness and difficulties in social relationships/behavior (e.g., hardship in making
and maintaining friendships, facilitated relationships with adults or younger people, lack of
autonomy, “social naivety”)
- Continued difficulties with social communication (e.g., inappropriate calmness, limited or,
conversely, very elaborate conversation and vocabulary about their one’s interests)
- Inappropriate social communication (e.g., too much familiarity, “professorial” explanations)
- Difficulties to understand other’s point of view
AQ/EQSCQ ADOS-2 (3)
ADI-R
Adults - Continued social awkwardness, difficulties with employment/emotional life











Factors masking ASD at any age
- Co-morbid psychiatric conditions (e.g., anxiety, hyperactivity, mood disorders, OCD)
- Factors such as female gender, ethnicity, multilingualism, socio-economic factors, and more advanced language skillsJanuary 2021 | Volume 10 | A*can be administered by a non-ASD specialist, ** to be used by a specialized ASD team. M-CHAT, Modified Checklist for Autism in Toddlers; CSBS, Communication and Symbolic
Behavior Scales; ADOS-2, Autism Diagnostic Observation Schedule, Second Edition; ADI-R, Autism Diagnostic Interview-Revised; AQ, Autism Quotient; EQ, Empathy Quotient; SCQ,
Social and Communication Questionnaire; SRS, Social Responsiveness Scale; CAST, Childhood Asperger Syndrome Test; RAADS, Ritvo Autism Asperger Diagnostic Scale-Revised.rticle 595734
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play a central role as an interface. Taking the time to gradually
expose the patient to the various instruments used during
therapy (e.g., monitoring equipment, needles, bandages) and
their sensory exploration could represent a mean to increase
the chances of optimal collaboration. If, despite these
arrangements, a crisis arises, the family/primary caregivers
remain of crucial importance in determining the sources of
discomfort. They will be able to provide insights on the
warning signs of crisis and effective strategies to reduce anxiety
used at home or elsewhere (e.g., stop talking, reducing noise,Frontiers in Oncology | www.frontiersin.org 5movement, and light, provide a sensory withdrawal room, use
visual distraction, engage in the patient’s specific interests).
Sixth, oncology providers should be aware that their patients,
regardless of age, might have an undiagnosed ASD and be
without a definitive neurodevelopmental diagnosis at the time
of the discovery of their neoplasm. In fact, even though ASD can
be diagnosed as early as age 2 years, most children remain
unidentified until after the age of 4 years (18). Particularly
relevant for the pediatric oncologist, this is an age at which a
peak in cancer diagnoses is observed. Of course, oncology teams
should not be screening every patient for ASD, but consultationTABLE 2 | Recommendations for the global care planning for patients with ASD in oncology.
Goal A: “Build a team”
1. Define leading medical and nursing staff members for the patient, with whom regular face-to-face communication is performed and who act as care coordinator(s).
2. Establish an accessible staff list of all providers involved in the patient’s care to ensure communication.
3. Educate the caregiving team, and ancillary staff on the patient’s specific needs (by meetings and electronic chart/panels in the room) and raise awareness that the
patient may be both over- and under-responsive to stimuli.
4. Communicate regularly (scheduled meetings) with the patient and his/her family/caregiving team.
5. Hold regular multidisciplinary team meetings with in/outpatient teams and include parents/family.
6. Continuously reinforce collaboration among the multidisciplinary team and parents/family.
7. Schedule satisfaction evaluations and leverage successes to build trust in caring for the patient.
8. Allow continuity of care (same providers and environments as much as possible).
Goal B: “Evaluate the patient’s needs & set the stage for optimal care”
1. Prior to care, comprehensively assess personal development, daily living, skills, and sensory needs in collaboration with the family/caregivers and nursing, speech and
occupational therapy teams:
a. involve parents and caregiving family members in establishing inpatient and outpatient routines,
b. involve and actively liaise with any outpatient care team member of the patient previously diagnosed with an ASD,
c. identify preferred communication style, self-regulation abilities, specific sources of anxiety and general behavioral triggers, and potential “safe” places and objects
eliciting self-regulation,
d. identify common expression modalities of distress, anger, sadness and pain,
e. involve a speech/language therapist for communication (e.g., develop/design pictorial boards and visual aids),
f. involve an occupational therapist to assist with sensory processing difficulties, and to identify calming sensory inputs (pressure, rocking, etc.) and implement into
patient room (colors, lights, objects),
g. involve a child life specialist to provide emotional support, playful activities, and strategies of stress reduction
2. Prepare the patient to new environments by any aids identified above (e.g., photographic booklets of spaces to enter, social stories).
3. Eliminate potential sources of irregular, stressful, loud or unusual sounds, lights, contact experiences (incl. people).
4. Provide single rooms for patients whenever possible.
5. Discuss and establish a dietary plan featuring known and routine foods (incl. with a hospital dietician)
Goal C: “Implement care and react to distress/crisis”
1. Coordinate clinical care to minimize sensory input and address environmental factors that contribute to sensory processing difficulties (e.g., auditory, tactile, nutritional
hypersensitivity), and busy environments (favor appointment slots in less active clinical daytime periods). Consider the possibility of consulting ASD individuals
(patient experts).
2. Anticipate and group procedures, provide ample time for preparation and ensure consistency of procedures and care (maintain sequences of vital signs, clinical
exams, discussions).
3. Identify/document individualized mitigation strategies that have proven to be effective.
4. Introduce cues (verbal or other) to prepare procedures or moments with potential triggers.
5. Maintain outpatient routines as much as possible while inpatient.
6. Continuously monitor for signs of imminent crisis (e.g., psychomotor agitation, increase of verbal output, stereotypies, verbal or physical aggression, self-harm).
7. In case of distress/crisis:
a. Safety first: create an area of protection, immediately stop any intravenous product or non-vital procedures.
b. If you feel there is the potential of losing control of the situation, immediately ask for help.
c. Initiate individualized mitigation strategies.
d. Perform post-hoc review of events:
i. identify the triggers for the crisis (e.g., symptom, fear, discomfort, pain)
ii. record the type of behavior (e.g., tantrums, screaming, self-injury, aggression)
iii. document which mitigation measures and their efficacy
iv. return information to healthcare team in charge of the patientJanuary 2021 | Volume 10 | Article 595734
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indicated in cases of suspicion (see Table 1). As psychologists
and other mental health professionals are an integral part of
individuals with cancer, most oncology teams will have easy
access to these resources. Nonetheless, while the first and most
important reflex should always be the timely referral to
specialized teams (i.e., psycho-oncology, social work,
psychiatry, depending on the local setting), an improved
awareness of front-line actors to the existence of standardized
screening instruments (Table 1) could contribute to the earlier
detection of ASD in situations where it does not seem apparent at
first glance (56–61).
Seventh, patients with ASD often experience physical
manifestations which overlap with common cancer- or cancer
treatment-related symptoms, such as pain, sleep disturbances
and fatigue, gastrointestinal (GI) problems or immune
dysregulation (27). These symptoms can easily be exacerbated
by the cancer-directed therapy or be misinterpreted.
Furthermore, difficulties in communication in patients with
ASD, and the lack of adapted and validated instruments, may
cause difficulties in their early identification and monitoring (62).
Five oncology-specific symptoms deserve special attention in
individuals with ASD. They are: a) pain, b) cancer-related
fatigue, c) neurological and behavioral toxicity, d) fever and e)
gastro-intestinal issues. We will discuss them individually due to
their high incidence/prevalence and importance for cancer-
associated outcomes. Our aim for this section is mainly to
provide awareness for the oncology team and hint at possible
solutions to some of the challenges they can pose in individuals
with ASD. More precise recommendations to manage these
cancer-related symptoms in ASD specifically cannot be
delineated due to the lack of evidence, and further research is
urgently needed. We wish to underline that children with ASD
are a) particularly at risk for misinterpretation/underestimation
of these symptoms, and b) underserved by the tools available to
measure them, due to many reasons whose discussion is beyond
the scope of this review.
Pain
Pain has a prevalence ranging 30–60% in oncology patients, and
its screening and assessment through validated instruments is an
integral part of cancer care (63, 64). However, the perception of
the “experience of pain” in individuals of all ages with ASD can
be difficult to assess by conventional scale measurements and
research in this area is ongoing (65–67). We strongly
recommend that caregivers/parents are closely involved in the
assessment of pain in individuals with ASD, and when possible,
self-assessment should be performed by a visual scale [e.g.,
adaptation of the Face Pain Scale-Revised (68)]. If the
individual with ASD is non-verbal or has ID, hetero-rating
scales will help to objectify manifestations of pain, favoring
recording of scores from close parents/family members/
caregivers. Although adjusted scales and measuring techniques
have been developed and validated for children with cognitive
limitations, data are still needed to adapt them to the specificities
of ASD (69). The use of the revised Face Legs Activity Cry
Consolability (rFLACC) pain assessment tool or the Non-Frontiers in Oncology | www.frontiersin.org 6Communicating Children’s Pain Checklist Postoperative Version
(NCCPC-PV) and the inclusion of parent/family member/
caregiver input in the interpretation of signs indicating pain is
the minimum standard (70). Taken as a whole, the incorrect
interpretation of behavioral patterns typical of individuals with
ASD can lead caregivers to assign the manifestations of pain
incorrectly to either an “exaggeration” or cause an underestimation
of the intensity of the pain experience.
Cancer-Related Fatigue (CRF)
Cancer-related figure (CRF) is the most prevalent symptom
experienced during the cancer trajectory (incidence of 40% at
diagnosis and 80–90% during chemo- and/or radiotherapy) (71).
CRF is defined as a distressing, persistent, subjective sense of
physical, emotional and/or cognitive tiredness or exhaustion
related to cancer or cancer treatment (72). No studies or
reviews published addressing how to measure and manage
CRF in the ASD population, which constitutes a major issue as
it significantly impacts quality of life and other treatment
outcomes (71, 72). Its perception and expression are most
likely altered in children and adults with ASD. In fact,
associated behavioral issues can be misleading in the
interpretation of CRF symptoms/signs and the communication
difficulties render the differentiation of fatigue vs. other
symptoms (e.g., sleepiness, dizziness, confusion, disorientation)
a challenging, if not an impossible task without the collaboration
of parents/caregivers. Furthermore, there is evidence to suggest
that maladaptive sleep patterns in this population are associated
with increased baseline daytime sleepiness, creating an additional
layer of complexity (73). As it is not clear whether the current
diagnostic criteria and the routine CRF management approaches
appropriately address the needs of patients with ASD, we
recommend that caregivers/parents are closely involved in the
assessments of fatigue in patients with ASD undergoing cancer
therapy. To allow the delineation of a personalized CRF-
expression pattern, these evaluations need to take the
individual communication/behavioral patterns into account, be
compared to baseline/prior signs/symptoms and be repeated in
several contexts. Once suspected, monitoring using the CRF-
expression pattern should occur on a regular basis.
Neurotoxicity
Neurological toxicity fromcancer therapyhasbeenwidely recognized
(i.e., headache, seizures, encephalitis,movementdisorders, peripheral
neuropathy) (74). With the development of immunotherapy, novel
and complex patterns to identify have emerged (i.e., polyneuropathy,
demyelination, leukoencephalopathy, aseptic meningitis). There is
evidence of an enhanced proinflammatory profile linked with major
depression, memory complaints and behavioral deficits, all of them
potentially present or enhanced in the context of ASD. As
neurological symptoms and cognitive deficiencies can be common
side effects of cancer treatment, individuals withASD could be at risk
for underdiagnosis. Sometimes these symptoms can remain even
after cessation severely impacting long-term quality of life. A similar
approach topain and fatigue should be used for neurotoxicity (see 4.1
and 4.2 above).January 2021 | Volume 10 | Article 595734
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Fever is a key symptom in the practice of oncology, as it can
indicate infectious complications resulting from chemotherapy-
induced myelosuppression. There is evidence to suggest that the
manifestation of fever is altered in ASD as children with this
condition rarely present with fever, and certain individuals even
display an improvement of the behavioral phenotype during
hyperthermia (75). The behavioral-state changes associated with
fever in ASD have been speculated to depend upon the selective
normalization of key components of a functionally impaired
locus coeruleus-noradrenergic system (76). Therefore, oncology
providers need to gather information about which signs and
symptoms could indicate fever in each individual with ASD and
communicate about them effectively within their teams (e.g., on-
call/night shifts), as this could prevent the underreporting or
underdiagnosis of potential life-threatening complications.
Gastro-Intestinal Issues
Digestive manifestations accompanying the cancer journey include
both lower (i.es., constipation, diarrhea) and upper gastro-intenstinal
(GI) symptoms (i.e., nausea/vomiting, abdominal pain) with a
prevalence ranging from 5–90% depending on treatment
modalities (77–80). In children with ASD, diarrhea and
constipation are among the most frequently reported (62, 81–85).
Moreover, medications administered to patients with ASD (b-
blockers and a2 agonists, dopamine-receptor blockers, opioid
antagonists, anticonvulsants, etc.) can also influence gut function.
Given the communication difficulties in individuals with ASD, any
atypical behavior (sleep disorders, irritability, food intolerance, self-
injurious behavior, posturing, grimacing, holding the abdomen,
squeezing the legs together, or walking around with a narrow gait
to hold the stool in) should trigger an evaluation for constipation.
Furthermore, little is known about the subjective experience of
chemotherapy-induced nausea/vomiting (CINV) in individuals
with ASD. For oncology providers, excessive nausea/vomiting to
minimallyorevennon-emetogenicdrugs couldconstitutea “redflag”
for ASD in a patient with other suggestive signs (see Table 1).RESEARCHON THE DELIVERY OF CANCER
CARE IN INDIVIDUALSWITH ASD
There is an urgent need for studies on the optimal cancer care for
patients with ASD. Clinical investigation should focus on a)
delineating the impact of cancer- and its therapy (incl.Frontiers in Oncology | www.frontiersin.org 7supportive care) on these individuals specifically, b) designing
and testing adapted instruments and/or strategies to measure
symptoms (e.g., CRF), c) adjusting the clinical environment to
facilitate care, and d) targeting providers and healthcare systems
for the delivery of effective training. Prospective trials should be
conducted with the participation and close collaboration of
direct caregivers (parents, families, etc.).LIMITATIONS AND CONCLUSIONS
The main limitation in our review is the lack of study-based
evidence on the cancer care of children, adolescents and adults
with ASD. Thus, an extensive, systematic review of the evidence
is not feasible at this time. As the number of pediatric and adult
patients with ASD in our oncology practices increases, our
recommendations at this time largely remain extrapolations of
available data from other clinical settings.
Nonetheless, we firmly believe that this should not hinder the
discussion of concrete measures that, if implemented, can
immediately benefit patients with ASD undergoing cancer
treatment. Giving providers (medical, nursing and affiliated staff)
the opportunity of improving their care of individuals with ASD is
a global priority. In the absence of higher-grade evidence, they are
intended as a call for vigilance of the particularities of these highly
vulnerable individuals. Further research is urgently needed in
order to improve our understanding of the impact of cancer-
and its therapy (incl. supportive care) on individuals with ASD,
which in turn shall help to develop instruments/strategies reliably
measuring quality and outcomes in this population during their
cancer care trajectory.AUTHOR CONTRIBUTIONS
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